BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33544209)

  • 1. Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway.
    Yi X; Lou L; Wang J; Xiong J; Zhou S
    Cancer Chemother Pharmacol; 2021 May; 87(5):647-656. PubMed ID: 33544209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
    Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
    Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7.
    Ding J; Zhao Z; Song J; Luo B; Huang L
    Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):597-604. PubMed ID: 29701752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
    Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
    Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal transfer of circular RNA FBXW7 ameliorates the chemoresistance to oxaliplatin in colorectal cancer by sponging miR-18b-5p.
    Xu Y; Qiu A; Peng F; Tan X; Wang J; Gong X
    Neoplasma; 2021 Jan; 68(1):108-118. PubMed ID: 33147048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytological effects of honokiol treatment and its potential mechanism of action in non-small cell lung cancer.
    Zhang J; Zhang Y; Shen W; Fu R; Ding Z; Zhen Y; Wan Y
    Biomed Pharmacother; 2019 Sep; 117():109058. PubMed ID: 31176168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
    Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
    Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2.
    Zeng H; Wang L; Wang J; Chen T; Li H; Zhang K; Chen J; Zhen S; Tuluhong D; Li J; Wang S
    Arch Biochem Biophys; 2018 Aug; 651():52-60. PubMed ID: 29802821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.
    Hu D; Li M; Su J; Miao K; Qiu X
    Genet Test Mol Biomarkers; 2019 Mar; 23(3):156-165. PubMed ID: 30807260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.
    Xu D; Lu Q; Hu X
    Cancer Lett; 2006 Nov; 243(2):274-80. PubMed ID: 16406853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
    Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
    Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
    Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
    Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation.
    Dastmalchi N; Safaralizadeh R; Hosseinpourfeizi MA; Baradaran B; Khojasteh SMB
    Mol Biol Rep; 2021 Feb; 48(2):1345-1357. PubMed ID: 33555529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells.
    Fang Y; Shen H; Cao Y; Li H; Qin R; Chen Q; Long L; Zhu XL; Xie CJ; Xu WL
    Braz J Med Biol Res; 2014 Jan; 47(1):60-9. PubMed ID: 24519092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA TTN-AS1 acts as sponge for miR-15b-5p to regulate FBXW7 expression in ovarian cancer.
    Miao S; Wang J; Xuan L; Liu X
    Biofactors; 2020 Jul; 46(4):600-607. PubMed ID: 32049388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
    Chang L; Hu Z; Zhou Z; Zhang H
    Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells.
    Park EJ; Min HY; Chung HJ; Hong JY; Kang YJ; Hung TM; Youn UJ; Kim YS; Bae K; Kang SS; Lee SK
    Cancer Lett; 2009 May; 277(2):133-40. PubMed ID: 19135778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
    Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
    Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.